吉非替尼
医学
耐受性
内科学
肺癌
不利影响
胃肠病学
化疗
随机对照试验
癌症
表皮生长因子受体
作者
Masahiro Fukuoka,Seiji Yano,Giuseppe Giaccone,Tomohide Tamura,Kazuhiko Nakagawa,Jean‐Yves Douillard,Yutaka Nishiwaki,Johan Vansteenkiste,Shinzoh Kudoh,Danny Rischin,Richard Eek,Takeshi Horai,Kazumasa Noda,Ichiro Takata,Egbert F. Smit,Steven D. Averbuch,Angela Macleod,A. Feyereislova,Rui-Ping Dong,José Baselga
摘要
To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839]; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with pretreated advanced non-small-cell lung cancer (NSCLC).
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
GingerF
Criminology34
学术文献互助
三四郎
yorha3h
Beansprout
脆蜜金桔
可耐的豪英
张欢馨
无极微光
干净的琦
Shawndy
嘉心糖
OsamaKareem
大力的灵雁
SimpleKwee
贪玩的秋柔
Momomo
Lzk
疯狂的千山
皖公网安备34019202002308
